BioPorto CEO: Not optimal looking back
Peter Mørch Eriksen, CEO in diagnostics company BioPorto, talks about the company's failed attempt to win EU backing for its NGAL patent.
by Benjamin Werner Christensen
The public Danish diagnostics company BioPorto announced today that it has decided to continue with a so-called divisional application for its NGAL cut-off patent based on a verdict from the European Patent Office (EPO). The actual NGAL patent was declared invalid by EPO on April 1.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
”It’s not like I’m leaving in tears today”
For abonnenter
BioPorto loses crucial patent trial
For abonnenter
